Nanobiotix

From Wikipedia, the free encyclopedia
Nanobiotix
Euronext: NANO
IndustryBiotechnology
Founded2003
Headquarters
Paris, France
Key people
Laurent Levy
( CEO)
ProductsNBTXR3 (Hensify®)
€2.54 million (2019)
Total assets€54.9 million (2019)
Number of employees
110 (2020)
Websitewww.nanobiotix.com

Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts.[1][2]

History[]

Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 [3] and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CIC Vizille; Masseran Gestion-CGE).

2003[]

  • Nanobiotix is founded based on research performed by Laurent Levy at SUNY Buffalo.[4]

2007-2010[]

  • Development of the NanoXray research program

2011[]

  • Start of the first phase I / II clinical study on NBTXR3 in humans. Commencement of treatment for the first patient recruited in the study.[5]

2012[]

  • Public listing of Nanobiotix on the Euronext Paris market and partnership with PharmaEngine.[6]

2014[]

  • Creation of the Nanobiotix's first US subsidiary in Cambridge, Massachusetts.[7]

2015[]

  • Start of the first clinical trial in the United States with NBTXR3 in Prostate Cancer.[8]

2017[]

  • Opening of a new facility to expand manufacturing capabilities, increase production capacity and prepare for commercialization.
  • FDA approval of Nanobiotix’s first immuno-oncology trial in the US. Opening of two new affiliates in Germany and Spain.[9]

2018[]

  • Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma[10]

2019[]

  • Launch of nine new phase I/II clinical trials, treating six cancer indications and involving 340 patients at the University of Texas MD Anderson Cancer Center[11]
  • Achievement of European market approval (CE marking) for NBTXR3 (Hensify®) in the treatment of locally advanced Sarcoma.[12]
  • Launch of Curadigm, the company’s new subsidiary dedicated to redefining the therapeutic balance between bioavailability, toxicity, and efficacy across the pharmaceutical industry[13]
  • Receives the 2019 Award for first-in-class NBTXR3[14]

2020[]

  • Fast track designation granted by U.S. FDA for investigation of first-in-class NBTXR3 in head and neck cancer.[15]

Therapeutics[]

Nanobiotix is currently in the clinical stage of developing NBTXR3, a “radioenhancer” that uses nanotechnology to make cancer cells more receptive to radiotherapy. NBTXR3 is an aqueous suspension of crystalline metallic nanoparticles approximately 50 nanometers in diameter, designed for injection directly into a malignant tumor. When exposed to ionizing radiation, NBTXR3 amplifies the localized, intratumoral killing effect. Upon activation by a standard dose of radiation, they release free radicals that destroys cancer cells, whilst the surrounding healthy tissues are preserved and receive the same dose of radiation as in standard radiotherapy.[16] The product is designed to enhance the overall efficacy of radiotherapy without resulting in additional side effects.[17][18][19]

Clinical Trials[]

NBTXR3 is currently being evaluated in 7 clinical trials around the world, and the development plan will include 16 clinical trials in 8 different types of cancer. In 2019, Nanobiotix launched a clinical collaboration with MD Anderson that includes 9 new Phase I/II clinical trials will be launched in the United States for NBTXR3 in multiple indications, including head and neck, pancreatic, lung, esophageal, and colorectal cancers.[20]

Nanobiotix obtained the first European marketing authorization (CE marking) for Hensify, the commercial name of NBTXR3, for the treatment of locally advanced Soft Tissue Sarcoma.[12]

Soft Tissue Sarcoma[]

Soft tissue sarcomas (STSs) are a rare type of cancer that develops in different types of soft tissues, including muscles, joint structures, fat, nerves and blood vessels. Although STS can develop at any anatomic site, it occurs in the extremities (arms and legs) in approximately 60% of cases. NBTXR3 completed Phase II/III clinical trials to treat Soft tissue sarcomas in combination with radiotherapy and surgery in April 2020.[8]

Head and Neck Cancer[]

Chemotherapy in combination with radiation is the standard treatment for locally advanced head and neck cancers in both the United States of America and the European Union. However, such treatment cannot usually be proposed to elderly and frail patients, as they are unable to endure the physical strain inherent in chemotherapy treatment.

NBTXR3 is currently in Phase II/III clinical trials to increase radiotherapy’s efficacy at treating Head and neck cancer. As of 2020, the study is recruiting participants in Taiwan.[21][22]

Hepatocellular carcinoma and liver metastases[]

According to the World Health Organization, liver cancer is currently the fourth most common cause of cancer death in the world. Surgical resection cannot be performed on many patients, while local and systemic treatment options are few in number and have significant limitations. Radiotherapy has been shown to improve outcomes for these patients, as a direct correlation between higher doses of radiation and increased survival rates have been observed from third party clinical trials. NBTXR3 is currently in Phase I/II clinical trials to increase radiotherapy’s efficacy at treating liver cancer. As of 2020, the study is recruiting participants in France.[23]

Rectal Cancer[]

Colorectal cancer is the third most common cancer in men and the second most common cancer in women. The five-year survival rate for patients with Rectal cancer is 64.4%, but varies greatly depending on the stage of the cancer and whether the cancer has spread.4NBTXR3 is currently in Phase I/II clinical trials to increase radiotherapy’s efficacy at treating rectal cancer. As of 2020, the study is recruiting participants in Taiwan.[24]

NBTXR3 in combination with immune checkpoint inhibitors[]

The NANORAY-1100 study is a multicenter, multi-arm, that aims to evaluate the safety, efficacy, and tolerability of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy in Locoregional recurrent (LRR) or recurrent and metastatic (R/M) head and neck squamous-cell carcinoma (HNSCC) and lung and Liver metastasis. It aims to evaluate the hypothesis that the combination of NBTXR3 activated by RT with anti-PD-1 therapy will act synergistically to enhance the therapeutic window of radiation therapy by maximizing the local effect, overcoming radio-resistance, increasing the efficacy of immunotherapy, and potentially producing an abscopal effect for improved distant tumor control. As of 2020, the study is recruiting participants in several states in the United States.[10]

Corporate structure[]

As of 2020:

Research and development[]

Nanobiotix has already won 10 public and private awards and owns 9 original umbrella patents.[26]

Pipeline:

  • NBTXR3, (a radiosensitizer), composed of hafnium oxide nanoparticles. Has an IND for a cancer trial (in combination with a PD-1 inhibitor).[27] Other clinical trials include : a Phase II/III in soft tissue sarcoma of the extremity and trunk wall,[28] a Phase I/II for hepatocellular carcinoma,[29] a Phase I/II for prostate cancer,[30] and a Phase I for squamous cell carcinoma of the oral cavity.[31]

References[]

  1. ^ "Homepage". Nanobiotix. 2019-02-28. Retrieved 2020-03-31.
  2. ^ "NANOBIOTIX 2019 Annual Results". Business Wire. 2020-03-17. Retrieved 2020-03-31.
  3. ^ "France Biotech".
  4. ^ GmbH, finanzen.net (2020-03-31). "Nanobiotix SA Company Profile". markets.businessinsider.com. Retrieved 2020-03-31.
  5. ^ "Nanobiotix Starts Clinical Trial with Lead Product NBTXR3" (PDF). Press Release. 2011-09-03. Retrieved 31 March 2020.
  6. ^ "Nanophotonics Firm Raises $18M in IPO". Photonics.com. 2012-11-13. Retrieved 2020-03-31.
  7. ^ "Massachusetts Biotechnology Council". Nanobiotix. 2019-12-17. Retrieved 2020-03-31.
  8. ^ Jump up to: a b "NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall - Full Text View". ClinicalTrials.gov. 2015-03-05. Retrieved 2020-03-31.
  9. ^ S.A., Nanobiotix (2017-12-26). "NANOBIOTIX : 2017 review and 2018 expected milestones". GlobeNewswire News Room. Retrieved 2020-03-31.
  10. ^ Jump up to: a b "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy - Full Text View". ClinicalTrials.gov. 2018-07-17. Retrieved 2020-03-31.
  11. ^ Kimmons, Rolaynne (2019-01-07). "MD Anderson Cancer Center and Nanobiotix announce a large-scale, comprehensive clinical collaboration on NBTXR3". MD Anderson Cancer Center. Retrieved 2020-03-31.
  12. ^ Jump up to: a b S.A., Nanobiotix (2019-04-04). "Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval". GlobeNewswire News Room. Retrieved 2020-03-31.
  13. ^ Ag, Biocom (2019-05-29). "Nanobiotix spins out Curadigm". European Biotechnology. Retrieved 2020-03-31.
  14. ^ "NANOBIOTIX Receives the 2019 Prix Galien Award for First-in-Class HENSIFY®". BioSpace. 2019-12-16. Retrieved 2020-03-31.
  15. ^ "FDA Grants Fast Track Designation to NBTXR3 in Locally Advanced Head and Neck Cancers". Targeted Oncology. 2020-02-10. Retrieved 2020-03-31.
  16. ^ "NanoXray video". nanobiotix.
  17. ^ Bonvalot, Sylvie; Rutkowski, Piotr L; Thariat, Juliette; Carrère, Sébastien; Ducassou, Anne; Sunyach, Marie-Pierre; Agoston, Peter; Hong, Angela; Mervoyer, Augustin; Rastrelli, Marco; Moreno, Victor; Li, Rubi K; Tiangco, Béatrice (2019-08-01). "NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial". The Lancet Oncology. 20 (8): 1148–1159. doi:10.1016/S1470-2045(19)30326-2. ISSN 1470-2045. PMID 31296491. Retrieved 2020-03-31.
  18. ^ "NCI Drug Dictionary". National Cancer Institute. 2 February 2011. Retrieved 2020-03-31.
  19. ^ Bonvalot, Sylvie; Rutkowski, Piotr L.; Thariat, Juliette; Carrère, Sébastien; Ducassou, Anne; Sunyach, Marie-Pierre; Agoston, Peter; Hong, Angela; Mervoyer, Augustin; Rastrelli, Marco; Moreno, Victor; Li, Rubi K.; Tiangco, Béatrice; Herraez, Antonio Casado; Gronchi, Alessandro; Mangel, László; Sy-Ortin, Teresa; Hohenberger, Peter; De Baère, Thierry; Le Cesne, Axel; Helfre, Sylvie; Saada-Bouzid, Esma; Borkowska, Aneta; Anghel, Rodica; Co, Ann; Gebhart, Michael; Kantor, Guy; Montero, Angel; Loong, Herbert H.; et al. (2015-03-03). "NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): A multicentre, phase 2–3, randomised, controlled trial". The Lancet. Oncology. 20 (8): 1148–1159. doi:10.1016/S1470-2045(19)30326-2. PMID 31296491.
  20. ^ Inacio, Patricia (2019-01-30). "Nanobiotix Plans Nine NBTXR3 Clinical Trials for Six Cancer Types". Immuno-Oncology News. Retrieved 2020-03-31.
  21. ^ "NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx - Full Text View". ClinicalTrials.gov. 2013-09-20. Retrieved 2020-03-31.
  22. ^ "A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer - Full Text View". ClinicalTrials.gov. 2016-09-15. Retrieved 2020-03-31.
  23. ^ "NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers - Full Text View". ClinicalTrials.gov. 2016-03-28. Retrieved 2020-03-31.
  24. ^ "A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer - Full Text View". ClinicalTrials.gov. 2015-06-08. Retrieved 2020-03-31.
  25. ^ "The management". Nanobiotix. 2019-02-28. Retrieved 2020-03-31.
  26. ^ "Company fact sheet" (PDF). Archived from the original (PDF) on 2010-11-27.
  27. ^ Nanobiotix gets FDA nod. Jan 2018
  28. ^ "NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall". ClinicalTrials.gov.
  29. ^ "NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers". ClinicalTrials.gov.
  30. ^ "NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma". ClinicalTrials.gov.
  31. ^ "NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx". ClinicalTrials.gov.[permanent dead link]

External links[]

Retrieved from ""